In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide MOTS-c | ||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Natural peptide | |
| Area | Longevity and mitochondria | Longevity and mitochondria | |
| Evidence | |||
| Amount of evidence | 338 (plus 34 on natural levels, listed separately) | 697 (plus 348 on natural levels, listed separately) | |
| Evidence level | Has results from studies in people | Results from animal studies onlyRegistered trials, no results from human studies | |
| Safety | |||
| Safety results | 13 (12 in people) | 12 (0 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 16 · 10 active35 more mention it but do not test it | 1 · 1 active3 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | NAD+ (nicotinamide adenine dinucleotide) | MOTS-c |
|---|---|---|
| Receptor activity and mechanismWhole body | 4011920 | 16491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 30 Oct 2026).
| Heart functionCardiovascular | 6372630 | 473710 |
|---|
| Mitochondrial functionWhole body | 25916 | 873651 |
|---|
| Inflammation markersSkin and wound | 12111 | 937518 |
|---|
| NeuroprotectionNervous system and cognition | 593524 | 312110 |
|---|
| PharmacokineticsPharmacology | 208210 | 22 |
|---|
| Bone and jointMusculoskeletal | 55 | 20515 |
|---|
| Liver fat and liver functionLiver | 17377 | 1414 |
|---|
| Glycemic controlMetabolic and weight | 3111 | 321913 |
|---|
| Lung injury and fibrosisRespiratory | 2323 | 826 |
|---|
| Adverse eventsWhole body | 55 | 981 |
|---|
| PainMusculoskeletal | 22 | 1313 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | NAD+ (nicotinamide adenine dinucleotide) | MOTS-c |
|---|---|---|
| Cardiovascular eventsCardiovascularCompared as: difference from placebo, in unitless | 0.089 unitless P value for 6-month composite MACCE rate comparison Dose studied: 10 mg/day7 daysn = 1802026 | No randomized trial result 5 results from other study designs. |
| Heart functionCardiovascularCompared as: difference from placebo, in unitless | 0.024 unitless P value for LVEF comparison Dose studied: 10 mg/day7 daysn = 1802026 |
0.089 unitless
P value for 6-month composite MACCE rate comparison
Dose studied: 10 mg/day7 daysn = 1802026
No randomized trial result
5 results from other study designs.
No randomized trial result
47 results from other study designs.
0.024 unitless
P value for LVEF comparison
Dose studied: 10 mg/day7 daysn = 1802026
No randomized trial result
47 results from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 16 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)
Anhui Provincial Hospital37 participants19 Dec 2023 to est. Mar 2026
Unresectable Hepatocellular Carcinoma
AgelessRx30 participants23 Jul 2025 to est. Apr 2026
Healthspan Improvement · Aging · Longevity
Beijing Children's Hospital180 participantsest. 1 Oct 2026 to est. 1 Dec 2028
Cardiac Dysfunction
35 more mention it but do not test it. They only measure it or name it in their text.
1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)
Hudson Biotech120 participants2 Feb 2026 to est. 17 May 2028
Prediabetes · Insulin Resistance · Overweight/Obesity
3 more mention it but do not test it. They only measure it or name it in their text.